423 results on '"Jentzsch, Madlen"'
Search Results
2. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
3. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
4. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
5. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
6. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma
7. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy
8. Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
9. Red blood cell distribution width (RDW) is associated with unfavorable functional outcome after transfemoral transcatheter aortic valve implantation
10. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
11. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
12. Compartment-specific mutational landscape of clonal hematopoiesis
13. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
14. Definitions of Acute Myeloid Leukemia and their clinical significance according to the WHO 2022 and ICC classification
15. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
16. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
17. Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
18. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
19. Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
20. Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
21. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
22. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
23. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
24. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation
25. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (Car) T Cell Treatment for Relapsed/Refractory Multiple Myeloma
26. Bendamustine, prednisone and bortezomib (BPV) induction therapy prior autologous stem cell transplantation (ASCT) in 135 newly diagnosed multiple myeloma patients: comparison between patients with normal and impaired renal function
27. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
28. Pretreatment CD34+/CD38– Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation
29. Remissionsparameter
30. Management of Patients Undergoing CAR-T Cell Therapy in Germany.
31. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
32. Steady‐state versus chemotherapy‐based hematopoietic cell mobilization after anti‐CD38‐based induction therapy in newly diagnosed multiple myeloma
33. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
34. MDS-337 HeMonitor: Machine Learning-Based Noninvasive Estimation of Hemoglobin (Hb) Value in Patients With Hematological Malignancies
35. POSTER: MDS-337 HeMonitor: Machine Learning-Based Noninvasive Estimation of Hemoglobin (Hb) Value in Patients With Hematological Malignancies
36. OA-04 Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
37. P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma
38. P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
39. P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
40. PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417
41. PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
42. P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
43. P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
44. Meningokokkensepsis ohne Liquorpathologie unter Eculizumabtherapie
45. Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
46. Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation
47. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
48. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients
49. Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation
50. Abstract CT124: A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.